<DOC>
	<DOCNO>NCT01159665</DOCNO>
	<brief_summary>To evaluate pharmacokinetic property intravitreal ocriplasmin 125 µg dose administer different time-points prior plan primary par plana vitrectomy ( PPV )</brief_summary>
	<brief_title>The Purpose This Study Evaluate Pharmacokinetic Properties Intravitreal Ocriplasmin Prior Planned Primary Pars Plana Vitrectomy ( PPV )</brief_title>
	<detailed_description>Open-label , ascending-exposure-time , single center trial total 36 subject enrol . The time remove vitreous record vitreous sample obtain begin vitrectomy determination ocriplasmin activity ; 32 subject receive 125 μg ocriplasmin intravitreal injection prior vitrectomy 4 subject receive ocriplasmin intravitreal injection prior vitrectomy ( control arm ) . Study drug administer mid-vitreous injection . The study eye examine study drug injection exclude retinal non-perfusion complication .</detailed_description>
	<mesh_term>Fibrinolysin</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Temazepam</mesh_term>
	<criteria>Male female subject age ≥ 18 Eye disease primary vitrectomy indicate Best Corrected Visual Acuity ( BCVA ) 20/800 good nonstudy eye Written inform consent obtain subject prior inclusion trial Proliferative diabetic retinopathy . Subjects vitreous hemorrhage vitreous opacification precludes either follow : visualization posterior pole visual inspection OR adequate assessment macula either Optical Coherence Tomography ( OCT ) and/or fluorescein angiogram study eye Aphakia study eye High myopia ( 8D ) study eye ( unless prior cataract extraction refractive surgery make refraction assessment unreliable myopia severity approximation , case axial length &gt; 28 mm exclusion ) . Subjects history rhegmatogenous retinal detachment either eye Subjects ocular surgery , laser photocoagulation treatment , intravitreal injection ( ) study eye prior three month Subjects laser photocoagulation macula study eye time Subjects uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 26 mm Hg spite treatment antiglaucoma medication ) Subjects history uveitis either eye . Subjects pregnant childbearing potential utilizing acceptable form contraception . Acceptable method birth control include intrauterine device , oral , implanted , injected contraceptive , barrier method spermicide . Subjects , Investigators view , complete visit investigation Subjects participate investigational drug trial within past 30 day Subjects previously participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>